Researchsemaglutidediabetic kidney diseaseglp-1 receptorflow trial

Review probes whether GLP-1 kidney benefit runs through podocyte senescence

Authors conclude podocyte-specific GLP-1 receptor signaling remains unproven despite FLOW showing semaglutide cut kidney events and cardiovascular death 24%.

By Priya Raman · Science Reporter

Sep 22 20:00 ETSource: Biochemical pharmacology

The wire

01A Biochemical Pharmacology review integrates GLP-1 receptor structures with podocyte and clinical data, finding evidence for anti-senescence effects largely extrapolated from whole-kidney or non-renal systems.
02Clinicians citing renal protection from semaglutide in diabetic kidney disease still lack a defined cellular mechanism, and urinary or circulating senescence biomarkers remain exploratory.
03The authors propose genetic and translational experiments to test podocyte-intrinsic GLP-1R signaling; multi-receptor GIPR and GCGR agonists show kidney signals but no proven receptor-level synergy.

From the source

GLP-1 receptor agonists and podocyte senescence in diabetic kidney disease: structural pharmacology, mechanistic evidence, and multi-receptor agonism
Biochemical pharmacology · 2026 Sep 23 · Yue H, Wang Y, Guo X et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42777788/